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S u m m a r y  
Evaluation of human histocompatibility leukocyte antigen (HLA) class II genes in 54 cases of 
tuberculoid leprosy (TL) and 44 controls has shown a positive association with HLA-DRB1 al- 
leles that contain Arg 13 or Arg7~ 71. Among TL patients, 87% carry specific alleles of DRB1 
Arg  13 or  ArgT~ 71 as compared to 43% among controls (p = 5 • 10 -6) conferring a relative 
risk of 8.8. Thus, susceptibility to TL involves three critical amino acid positions of the [3 
chain, the side chains of which, when modeled on the DR1 crystal structure, line a pocket 
(pocket 4) accommodating the side chain of a bound peptide. This study suggests that disease 
susceptibility may be determined by the independent contribution of  polymorphic residues 
participating in the formation of a functional arrangement (i.e., pocket) within the binding cleft 
of  an HLA molecule. 
L eprosy is a chronic infectious disease caused by a rela- tively nontoxic microorganism, Mycobacterium leprae. In 
the natural history ofM. leprae infection, >95% of  individ- 
uals resist disease by establishing protective immunity and 
only the minority develops leprosy (1). Nevertheless, lep- 
rosy is a major world health problem affecting an estimated 
10.6 million patients in the world of  which two thirds 
(62%) are found in Southeast Asia and 34% in Africa (2). 
Once leprosy becomes established, there is a wide spectrum 
of  clinical manifestations. Tuberculoid leprosy (TL) 1 and 
lepromatous leprosy (LL) are two opposite poles in the 
spectrum, representing stable disease forms with distinct 
immunopathological and clinical findings. Borderline lep- 
rosy is an intermediate, unstable form of the disease with 
clinical and pathological manifestations between the two 
poles (2). 
TL is the localized, hyperactive form of  leprosy. As in 
healthy, exposed individuals, the lepromin skin test is posi- 
tive and there is a vigorous in vitro proliferation of PBL to 
1 Abbreviations used in this paper: LL, lepromatous leprosy; rr, relative risk; 
TL, tuberculoid leprosy. 
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mycobacterial antigens. However, in the skin lesions, very 
few if any acid-fast bacilli are present (3). At the other end 
of  the spectrum, LL is the anergic, widespread form of lep- 
rosy. Macrophages loaded with acid-fast bacilli accumulate 
in the lesions, but the lepromin test is negative and PBL do 
not proliferate in vitro to M. leprae antigens (3). It appears 
that different immunopathogenic mechanisms operate in 
different disease forms. Since there is no association be- 
tween disease forms and different M. leprae strains or expo- 
sure levels to M. leprae, the reaction of  the host may deter- 
mine the form of the disease that develops. Previous family 
and population studies have linked these host factors to 
HLA class II molecules. 
In Asian-Indian families with leprosy, TL was associated 
with DR2 (4). This association has also been detected in 
sporadic TL patients from ethnically diverse populations, 
e.g., India, Japan. Thailand, and Korea (5-11), whereas an 
association with DR.3 has been reported in two distinct 
populations from Venezuela and Surinam (12, 13). In re- 
gard to LL, although early reports suggested that the Dl<2 
association involves only TL (5, 8, 12, 14), other subse- 
quent reports do not confirm this finding (7, 9, 15-17). In 
all these studies, serological HLA typing was employed as 
the typing method, therefore, HLA differences at the too- 
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lecular level between patients and controls could not be 
evaluated. 
HLA molecules are receptor cell-surface glycoproteins 
that bind peptides and present them to the T cells (18, 19). 
This interaction causes stimulation o f  the T cell and activa- 
tion o f  an immune response. There are class I and II HLA 
molecules with different domain organization but similar 
structure (20, 21). Polymorphic residues in both class I and 
I! molecules are clustered within the peptide-binding re- 
gion and are responsible for the different peptide specifici- 
ties observed for different histocompatibility molecules. 
Both class I and II molecules have allele-specific binding 
motifs (22, 23). Peptides bound to class I are o f  defined 
length (8-10 residues); their motifs are characterized by a 
strong preference for a few side chains at some positions in 
the peptide and wide tolerance for many side chains at the 
other positions (24). Peptides bound to class II molecules 
are longer with no apparent restriction on peptide length 
(25, 26). The main chain atoms of  the peptides form hy- 
drogen bonds with HLA residues conserved in most class II 
alleles, and the side chains are accommodated by polymor-  
phic pockets in the binding site. These pockets appear to 
determine the peptide specificity o f  different class II pro- 
teins (27). Polymorphic residues in the binding cleft o f  
HLA class II molecules, therefore, control the binding of  
foreign peptides, and indirectly, the immune response to 
these peptides. The objective o f  this study was to use a 
DNA-based typing procedure to identify polymorphic res- 
idues within the binding cleft that may be associated with 
the disease, TL. 
Materials and Methods  
Populations Tested and Statistical Analysis. 54 unrelated patients 
with sporadic TL were randomly selected from major hospitals in 
Delhi. These patients were from the north Indian states of Pun- 
jab, Haryana, Uttar, Pradesh, Bihar, and Delhi. None of them 
had a history of familial leprosy. The patients were classified ac- 
cording to the tLidley and Jopling criteria (28) by clinical exami- 
nation and a review of their clinical histories. Skin-slit smear bacte- 
riology and histopathological examination of skin biopsy specimens 
were performed in all patients. Preliminary results on the typing 
of some of the patients have been previously published (29). 44 
unrelated healthy individuals constituted the control group. None 
of them had a family history of leprosy. They were all matched 
with patients for socioeconomic status and were living in the 
same area as the patients. 
The chi square test with Yates' correction was used to evaluate 
the differences of the allelic frequencies between various groups. 
To correct for the multiple comparisons carried out, the apparent 
significance level was multiplied by the number of statistical tests 
(30). Fisher's exact test was used to determine the statistical signif- 
icance of the differences between the subtypes of DIL6-positive 
TL patients and controls because of the relatively low number of 
subjects involved in those cases. For haplotypes showing a statisti- 
cally significant difference in frequency between patients and 
controls, relative risk was calculated as: rr = [Pd (1-Pc)]/[1-Pd) 
Pc], where Pd and Pc are the frequencies of individuals positive 
for the allele(s) among patients and controls, respectively. 
DNA Extraction. A standard phenol-chloroform extraction 
method (31) was used for the isolation of high molecular weight 
genomic DNA from whole blood samples and from a reference 
panel ofB lymphoblastoid cell lines (32) that constituted the pos- 
itive and negative controls for the amplification and hybridization 
reactions. 
PCR Amplification of Genomic DNA. Locus and allele-spe- 
cific amplifications of genomic DNA with the PCP,, were per- 
formed for D1LBI-, DtLB3-, DR.B4-, DILB5-, and DQBl-asso- 
ciated alleles. The primers used in the PCtL and the amplification 
conditions have been described earlier (31). Cycling was per- 
formed with a thermal cycler (model 9600; Perkin-Elmer Cetus 
Corp., Norwalk, CT). Amplified samples were electrophoresed 
in a 1% agarose gel containing ethidium bromide and were visu- 
alized under UV light. 
Dot Blot and Hybridization. Amplified DNA was blotted on 
Hybond N +  nylon transfer membranes (Amersham Corp., Ar- 
lington Heights, IL). The membranes were hybridized with the 
probes in a hybridization incubator (P, obbins Scientific Corp., 
Sunnyvale, CA). A panel of sequence-specific oligonucleotide 
probes (SSOP), described earlier (31), was used with some modi- 
fications. The oligonucleotide probes were labeled with digoxi- 
genin-11-dUTP (Boehringer Mannheim Corp., Indianapolis, IN) 
using terminal deoxynucleotidyl transferase (Boehringer Mann- 
helm) according to the manufacturer's instructions. The labels 
were detected by sheep anti-digoxigenin antibody fragments 
(Fab) conjugated to alkaline phosphatase (Boehringer-Mannheim) 
diluted at 150 mU/ml. Nitro blue tetrazolium and 5-bromo- 
4-chloro-3-indolyl phosphate (all from Sigma Chemical Co., St. 
Louis, MO) were used as the chromogenic substrates. 
Results  and Di scuss ion  
54 unrelated sporadic cases o f  TL and 44 healthy controls 
from northern India were typed for HLA class II genes 
(DRB1, B3, B4, B5, and DQB1) by amplification o f  D N A  
with the PCIL and hybridization with SSOP. Frequencies 
o f  the H L A - D R B 1  alleles in the control population were 
similar to those reported for other Asian-Indian popula- 
tions (5, 33, 34). The number  o f  individuals positive for 
each o f  the different D1LBI* alleles in the two populations 
of  TL patients and controls is shown in Table 1. Notice-  
ably, none of  the alleles as defined by DNA-based HLA 
typing shows a statistically significant difference between 
control and TL patients. 
However,  upon careful evaluation, there are certain dif- 
ferences between the two populations that are very instruc- 
tive. The comparable frequency of  alleles 1501 and 1502 
within TL and control groups (32 vs 37% in TL patients 
and 14 vs 18% in control subjects) suggests that none of  
these two alleles has an advantage over the other in terms 
of  disease susceptibility. Therefore, the single amino acid 
difference [V(1501) --) G(1502)] at codon 86 does not play 
a major role in disease susceptibility and allows these two 
alleles to be considered as a single entity (DRBl*15). 
However,  as shown in Table 2, the number o f  TL patients 
positive for DRB1*15 (1501 + 1502) is significantly higher 
as compared to the number o f  control individuals positive 
for the same alleles (TL [37 of  54] 69%; control [14 o f  44] 
32%; uncorrected p = 0.0007 and corrected for nine tests 
830 Association of Argl3/Arg 7~ of HLA-DRB1 with Tuberculoid Leprosy 
T a b l e  1. HLA-DRB1 Typing of TL Patients and Controls T a b l e  2. Association of DRB1 Alleles with TL 
Alleles Patients Controls rr Corrected p Patients Controls 
(n = 54) (n --- 44) 
Alleles n ~ n % Corrected p 
n = 5 4  % n = 4 4  % 
DRBI*15 37 69 14 32 4.7 0.0063* 
DRBI*0101 3* 6 4 9 NS* 
DRBI*0102 0 - -  1 - -  
DRBI*1501 17 32 6 14 NS 
DRB1*1502 20 37 8 18 NS 
DRBI*1602 1 - -  1 - -  
DR_BI*0301 6 11 12 27 NS 
DPd31*0401 1 - -  2 - -  
DRBI*0403 2 - -  3 7 NS 
DRBI*0406 1 - -  0 - -  
DRBI*0409 0 - -  1 - -  
DRBl*1101 4 7 3 7 NS 
DRBl*1103 0 - -  1 - -  
DRBl*1104 1 - -  1 - -  
DRB1*1106 0 - -  1 - -  
DRB1*1201 0 - -  2 - -  
DRB1*1202 2 - -  1 - -  
DRBl*1301 4 7 8 18 NS 
DRB1*1302 1 - -  0 - -  
DRBI*1401 1 - -  0 - -  
DRB1*1402 0 - -  1 - -  
DRBl*1403 0 - -  1 - -  
DRBl*1404 12 22 4 9 NS 
DRBI*0701 9 17 15 34 NS 
DR_BI*0803 0 - -  2 - -  
DR_B1*0901 2 - -  1 - -  
DPd31*1001 9 17 3 7 NS 
*Number of individuals positive for a particular DRB1 allele. 
*Statistical analysis was performed in 10 out of 26 DRB1 alleles. The 
remaining 16 were not tested for statistical differences because two or 
fewer instances were observed in both control and TL patients, 
p = 0.0063, rr = 4.7). This  suggests the presence  o f  
epitope(s) on  the D R B 1 * 1 5  sequence  that is impor tan t  for 
T L  susceptibility. Addit ional ly,  a m o n g  D R 6 - p o s i t i v e  ind i -  
viduals ( D R 6  includes D R B 1 * 1 3  and D R B 1 * 1 4  alleles), 
on ly  t w o  alleles occur  wi th  reasonable frequencies in our  
popula t ion,  namely  D R B 1 * 1 3 0 1  and D R B l * 1 4 0 4  (Table 
2). It was observed  that the f requencies  o f  these t w o  alleles 
in the TL  patients and controls  w e r e  character ized by an 
inverse relationship. A m o n g  T L  patients (Table 2) there  
was an increased n u m b e r  o f  cases posi t ive for D R B 1 * 1 4 0 4  
(12 o f  16, 75%) as c o m p a r e d  to controls  (4 o f  12, 33%; 
p = 0.034) and a decreased n u m b e r  o f  TL  cases posi t ive 
for D R B 1 * 1 3 0 1  (4 o f  16, 25%) as compared  to controls  
(8 o f  12, 67%; p = 0.034).  D R B l * 1 4 0 4  was also in-  
creased a m o n g  D R 2 - n e g a t i v e  ( D R 2  includes D R B l * 1 5  
DR6posi t ives  n =  16 % n =  12 % 
DRBl*1301 4 25 8 67 0.17 0.033 ;~ 
DRBl*1404 12 75 4 33 6 0.033 
DR2negat ives  n =  15 % n =  27 % 
DRBl*1404 6 40 1 4 7.1 0.034~ 
*Statistical analysis was performed in 10 out of 26 DRB1 alleles. The 
remaining 16 were not tested for statistical differences because two or 
fewer instances were observed in both control and TL patients. The p 
value correction factor is therefore 9 (DRB1*1501 and DRBl*1502 
were combined into one allele). 
*Fisher's exact test was used to determine statistical significance in this 
group. 
~Statistical analysis was performed in 7 out of 18 alleles present in the 
DR2-negative individuals. The remaining 11 were not tested for statis- 
tical differences because two or fewer instances were observed in both 
control and TL patients. The p value correction factor is therefore 7. 
and D R B I * 1 6  alleles) T L  patients (6 o f  15, 40%) as c o m -  
pared to D R 2 - n e g a t i v e  controls (1 o f  27, 4%); unco r rec t ed  
p = 0.0048, and cor rec ted  for seven tests p = 0.034 w i t h  
r r =  7.1 (Table 2). Since alleles DRB1*1301  and 
D R B l * 1 4 0 4  are splits o f  the serologic specificity D R 6 ,  this 
inverse relat ionship o f  the two  subtypes may  very  wel l  ex -  
plain why ,  in previous  serological  studies, the impor tance  
o f  the D R 6  specificity w e n t  undetec ted .  
T h e  ident i f icat ion o f  the D R B 1 * 1 5  alleles that w e r e  
posi t ively associated w i t h  TL,  the significantly increased 
numbers  o f  T L  patients posi t ive for D R B l * 1 4 0 4  a m o n g  
D R B 1 * 1 5  negat ive  cases, and the inverse relat ionship o f  
D R B I * 1 3 0 1  and D R B 1 * 1 4 0 4  alleles a m o n g  D R 6 - p o s i t i v e  
cont ro l  and T L  individuals focused our  a t tent ion  on  the 
amino  acid residues that w e r e  different b e t w e e n  the nega-  
t ively and posi t ively associated allelic forms. W e  reasoned 
that the most  impor tan t  amino  acid posit ions for disease 
susceptibility w o u l d  be those that differed in the negat ively 
as compared  to the posi t ively associated alleles. These  
amino  acid residues were  found  to be  located at posit ions 
[313, [537, [570, and [571 (Fig. 1). T h e  two  posi t ively associated 
alleles D R B l * 1 5  and D R B 1 * 1 4 0 4  w e r e  character ized by 
arginines at posi t ions [313 and [37~ respectively.  A d d i t i o n -  
ally, it was no t iced  that the D R B l * 1 3 0 1  allele is character-  
ized by S 13, D 7~ and E vl wh ich  represent a negative charge, 
whereas  D R B 1 * 1 4 0 4  is character ized by G 13, R 7~ and R 71, 
w h i c h  represent  a posi t ive charge. Disease association was 
therefore  r eexamined  using the presence o f  arginine at 
these three positions and the absence o f  negat ively charged 
amino  acids in any o f  the same posit ions as criteria, regard-  
less o f  allelic typing. Those  alleles inc lude  D R B l * 1 5 0 1  
(R13, Q70, A71), D R B l * 1 5 0 2  ( R  13, q70, A71), D R B l * 1 4 0 1  
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DRBI*1301 E Y S T H H Y D 
DRBI*1404 . . . .  Y - H A 
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67 
Y A Negative Association among DR6 positive individuals. 
H E Positive Association among DR6 positive individuals. 
- Positive Auociafion 
F igure  1. Residues that differ among DR. alleles that are positively and negatively associated with TL. Amino acid residues are indicated that are differ- 
ent between DRB1*1301 and DRBl*1404 or between DRB1*1301 and DRB1*15 allele. Residues at positions 13, 37, 70, and 71 were different in both 
comparisons. DRBl*1301 (S13N37D7~ 71) "--q' DPd31*1404 (GI3F37R7~ or --) DRB1*15 (R13S37Q7~ 
(S 13, R 7~ R71), DR_B1*1404 (G 13, R 7~ R71), DRBI*0901 
(F 13, R 7~ R.71), and DRBI*1001  (F 13, R. 7~ R;1). As shown 
in table 3, the phenotype Arg 13 positive or Arg 70/71 positive 
was overrepresented among patients as compared to con-  
trols (TL patients [47 o f  54] 87%; controls [19 o f  44] 43%; 
p = 5 • 10 -6, IT 8.8). Characteristically, most o f  the pa- 
tients were DRB1-Arg  ~3 positive (37 of  54, 69%). Among  
those patients that lacked DRB1 alleles with Arg 13, there 
was a significant increase in D R B t  alleles that were positive 
for Arg 7~ (TL patients [10 of  16] 63%; controls [5 of  29] 
17%; p = 0.003). 
When  the criterion o f  association was expanded to in- 
clude alleles with any positive charges at positions 1313 or 
~70/71, alleles DRBI*0401 (H 13, QT0, K71), DRBI*0403  
(H13 QV0, R7I), DRBI*0406  (H 13, Q70, R71), and 
DRBI*0409  (H 13, QT0, K71) were also counted among 
those that could confer susceptibility. In addition to the 
D R B I * 0 4  alleles, no others satisfied this criterion in our 
population. Statistical analysis showed that by including the 
D R B l * 0 4  alleles within the group of  alleles that confer sus- 
ceptibility, the p value of  "positive charge at positions 613 
or [37~ (TL patients [49 o f  54] 92%; controls [23 of  44] 
52%; p = 25 • 10 -6) did not show a better association as 
compared to the p value of  "Arg I3 or Arg 7~ (p = 5 • 
10 -6) whereas rr was at a comparable level (8.9 vs 8.8) (Ta- 
ble 3). T h e  frequency of  all D R B I * 0 4  alleles combined  
in the Asian-Indian population is between 7 and 10% (33, 
34), which is comparable with that o f  D R B l * 1 4  alleles. 
I f  these D R B I * 0 4  alleles were positively associated with 
the disease there should have been an increased frequency, 
though not neccessarily statistically significant, o f  TL pa- 
tients positive for D R 4  as compared to controls. However ,  
such an increased frequency was not observed (Table 1). 
Table 3. Association of DRB1 Shared Epitopes with TL 
Epitopes Patients Controls rr p 
p13  o r  1~ 70/71 
RI3  
Positive charge at 
~13 o r  ~70/71 
R 13 negatives 
p~70/71 
n =  54 % n =  44 % 
47 87 19 43 8.8 5 X 10 -6 
37 69 14 32 4.7 0.0003 
49 90 23 52 8.9 25 5< 10 .6 
n =  16 % n = 2 9  % 
10 63 5 17 7.1 0.003 
Therefore,  the positive charge at positions [313 o r  ~70/71 
did not improve the association with the disease, and it is un-  
likely that the alleles DRBI*0401, DRBI*0403, DRBI*0406, 
and DRBI*0409  are among those that confer susceptibility. 
The  absence of  statistically significant differences in the 
numbers of  individual DRB1  alleles between TL patients 
and controls in contrast to the highly statistically significant 
difference for Arg 13, Arg 7~ in the same population is very 
likely due to the relatively small size of  the population sam- 
ple analyzed and to the typing method employed (DNA-  
based typing), which substantially increases the number  of  
detected alleles. However ,  irrespective o f  the absence o f  
statistically significant alMic differences, the DNA-based  
typing has provided amino acid sequence information, 
hence, eliminating the need to establish allelic associations 
before a valid association can be established at the amino 
acid level. Therefore, identification of  particular amino 
acid(s)/epitopes present in more  than one allele and pre- 
disposing to disease susceptibility may become  apparent 
by studying populations, whose size can be smaller, as 
compared to the large size o f  a population that would be 
required if allehc associations were to be established. Rare 
alleles such as DRB1*1401 and DRBI*0901 that are repre- 
sented in 1-3% of  this populat ion would only signifi- 
cantly increase in a population o f  over 1,000 individuals. 
DRBI*1001,  which is a more frequent allele (4-6%) in this 
population (33, 34), already shows the tendency of  an asso- 
ciation (p = 0.18) yet does not reach significant levels. N o  
definitive statement, therefore, can be made concerning the 
association of  these three alleles with TL. However ,  the 
presence of  Arg 7~ in their DR[3 chains suggests that these 
alleles may play a role in disease susceptibility. 
The amino acid substitution at position 37 was not found 
to be significantly different between patients and controls. 
To  examine whether  other HLA genes within the M H C  
that are in linkage disequilibrium with H L A - D R B 1  alleles 
influence the association of  TL, the distribution o f  the al- 
lelic forms o f D R B 3 ,  DRB4,  DRB5,  and DQB1 genes was 
evaluated. N o  significant differences were found in the fre- 
quencies of  these alleles between TL patients and controls 
(data not shown). Furthermore, no linkage disequilibrium 
was identified between Arg at position 13 or 70/71 of  the 
DRB1 gene and other D R B  or D Q B  genes. 
It is noteworthy that from the crystal structure of  a 
H L A - D R  molecule the side chains o f  positions 13, 70, and 
71 are in close proximity (19, 20), and that charge differ- 
ences in the local environment  may affect the binding of  
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peptides to the cleft or their recognition by T C R  (Fig. 2 
A). Reminiscent of  this observation is the finding that in 
HLA-DR.1, the side chains of  residues 13, 70, and 71 line a 
pocket, pocket 4 (Fig. 2 B) that accommodates a Gln side 
chain from the hemagglutinin peptide (27). The exact crys- 
tallographic structure of  other HLA-DR. alleles with an Arg 
at positions 13 or 70 and 71 is not known. It is very likely, 
however, that the side chains of  these amino acids will also 
contribute to the formation of this pocket. 
Our finding suggests that the presence of Arg at positions 
13 or 70/71 in pocket 4 of  the DRB1 alleles confers sus- 
ceptibility to TL. We propose that the presence of a posi- 
tive charge generated by Arg at positions 13 primarily or 70 
and 71 secondarily may influence a critical site within the 
binding groove of  the DR. chain that affects peptide bind- 
ing and/or T cell interactions in the immune response asso- 
ciated with TL. In support of  this hypothesis are a number 
Figure 2. Presentation of amino acids forming pocket 4 of the DP,.1 
crystal structure. (,4) Crystal structure is shown as spherical model where 
ct chain is shown in white and 13 chain in yellow. The pictures are gener- 
ated using GRASP (35). The three residues 1313 Phe (blue), 1370 Gin (green), 
and [371 Arg (red) are shown on the structure. (B) Pocket formation is 
shown as dotted surface. The walls of the pocket are formed by residues 
13 70 7I 74 78 13 Phe (blue), 13 Gin (green), 13 Arg (red), 13 Ala (yellow), 13 Tyr (yel- 
9 2 low), and o~ Gin (white). These residues are within 12 A distances. 
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of  in vitro studies performed independently by other inves- 
tigators (36-38) wherein positions 13, 70, and 71 were 
shown to be direcdy involved in antigen-specific T cell re- 
sponses. These studies have examined the amino acid resi- 
dues at various positions of  the DR.~3 chain that are impor- 
tant for antigen-specific T cell recognition. By employing 
L cell transs expressing a single D R  allele and site- 
directed mutagenesis it has been determined that among 
amino acid residues 9, 11, 13, 28, 30, and 37 that are local- 
ized to the floor of  the binding groove, substitutions at po- 
sition 13 more frequently eliminated T cell recognition 
than substitutions at any of  the other five positions (36-38). 
Additionally, substitutions in the r at positions 70, 
71, and 74 could drastically affect T cell responses (36-38). 
Furthermore, studies on the association of  M H C  class II 
molecules with chronic autoimmune disorders have shown 
that amino acids at positions 67, 70, 71, and 74 of HLA- 
DRB 1 are associated with susceptibility to rheumatoid ar- 
thritis. In rheumatoid arthritis, the DRB1 alleles associated 
with the disease involve amino acid substitutions at posi- 
tions 70, 71, and 74 that change the local charge of  the re- 
gion affected by these amino acids to a more positive one 
(39, 40). Recently, characterization of  peptides bound to 
the DRBI*04 alleles which are positively (DRBI*0404) 
and negatively (DRBI*0402) associated with rheumatoid 
arthritis revealed that both alleles have identical require- 
ments at the anchor residue pl  and at p6 but a substantially 
different requirement at position p4 (41). DRBI"0404 
binds peptides with a negative charge at p4 whereas the re- 
verse is true for DRBI*0402 which binds peptides with a 
positive charge at the same position. Since these two HLA 
alleles are different in positions 67, 70, and 71 and positions 
70 and 71 participate in the formation of pocket 4, these 
findings emphasize the importance of the structural charac- 
teristics of  these HLA alleles at this region and strongly sug- 
gest that pocket 4 of  these two HLA molecules determines 
the kind ofpeptides that will be accommodated. 
Another illustration of  the importance of  this region is 
the reported association of  chronic beryllium disease with 
certain DPB1 alleles. A change at position 69 of the DPB1 
gene from a lysine to a glutamic acid has been reported to 
be associated with chronic beryllium disease, a lung dis- 
order related to beryllium exposure, and characterized by 
the accumulation in the lung of beryllium-specific CD4 § 
M H C  class II-restricted T lymphocytes (42). It is notewor- 
thy that position 69 of  the DP[3 chain corresponds to posi- 
tion 71 of the Dtk[3 chain and that the amino acids in- 
volved cause a major charge shift from positive (R.) to 
negative (E). 
The importance of  a similar region in class I molecules 
has been previously indicated by other studies (43) that in- 
volve virus-specific, Kb-restricted cytotoxic effector cells 
responding to K b mutants. The bm 1 mutant with altered 
amino acids at positions 152, 155, and 156 is the only one 
that affects the virus-specific cytotoxic effector cells so that 
characteristically, all clones lose their reactivity (43). It is 
interesting that none of the other bm mutants affects the 
cytotoxic cells so uniformly. These positions in the class I 
molecule correspond to positions 66, 69, and 70 of  the 
DR[3 chain. Thus, both class I and II molecules appear to 
influence T cell recognition by changes in amino acids lo- 
cated in equivalent portions of  the HLA molecule (class 
I-orS6/class II-[37~ 
These independently reported observations using in vitro 
functional analysis o f t  cell clones and HLA disease associ- 
ation studies are, therefore, consistent with our conclusions 
that specific positions on the HLA [3 chains define a critical 
site that appears to play a more  pronounced role in T cell 
recognition and activation. This effect may be the result o f  
more than one amino acid substitution. A particular site 
within the groove may be influenced by several amino acid 
positions. Indeed, the formation of  pockets as illustrated in 
the crystal of  DRl- in f luenza  peptide suggests that the 
binding of  a foreign peptide is influenced by a number  of  
side chains lining a particular pocket  on the HLA molecule. 
Characteristically, pocket 4 is formed by the side chains of  
amino acids e0 [313, [3v0, [37l, [374, and [378. Substitutions on 
any of  these positions that would affect the local charge 
such as Arg at position 13 or Arg at positions 70 and 71 
may both have the same effect as they will probably ac- 
commodate  the binding of  a negatively charged residue of  
the foreign peptide. This may indeed be the case as it has 
been reported that H L A - D R w 1 7  (DRBI*0301),  which 
has arginine instead of  alanine at position [374, prefers as- 
partate or glutamate at the position that corresponds to he-  
magglutinin glutamine 311 (44, 45). The  presence of  Arg 
at 74 may also explain the reported association of  TL with 
D R 3  in two ethnic groups (12, 13). W h e n  these polymor-  
phic positions that form the pocket  involve substitutions 
that result in potent charge modifications, the binding of  a 
peptide or o f  a T C R  may be affected, provided the intro- 
duced modifications result in a net gaining or losing charge. 
Howeve r  the apparent lack of  association with D R B I * 0 4  
alleles, which have a histidine at [313, suggests that the mere  
presence of  a positive charge in this region may not be ade- 
quate and that arginine is instrumental in terms of  selecting 
the appropriate peptide for binding, 
In our study involving TL patients, the association with 
H L A - D R  alleles including D R 2  was confirmed. Further- 
more,  it appears that the associations of  DR[3 Arg 13 or 
Arg 7~ with TL may be specific for this form of  the dis- 
ease, A recent study examining TL and control individuals 
from the same geographical area as our population (46) by 
HLA oligotyping, reported the increased frequency of  
D R B l * 1 5  alleles but did not detect the inverse relationship 
of  DRBI*1301  and DRB1*1404 within the DR6-posi t ive  
individuals. This may be related to the rather small number  
of  cases (28 TL patients) who  were examined. 
In TL, it is likely that peptide(s) originating from M. lep- 
rae binds preferentially to HLA allelic forms characterized 
by Arg at positions 13 or 70-71 and stimulates particular T 
cell clones that result in a detrimental immune  response of  
TL. Identification of  peptide motifs that bind the different 
allelic forms associated with the disease would contribute 
significantly to the search for M. teprae antigenic determi- 
nants that initiate this response, and possibly for self-protein 
and peptides that become the targets. Our  findings suggest 
that the disease-associated alleles will be characterized by a 
binding mot i f  that includes a negatively charged amino acid 
at position 4 (numbering is based on the hemagglutinin 
peptide that binds DR1  [27]). 
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